🚀 VC round data is live in beta, check it out!
Atrys Health Valuation Multiples
Discover revenue and EBITDA valuation multiples for Atrys Health and similar public comparables like Healius, Australian Clinical Labs, Humana, Prenetics Global and more.
Atrys Health Overview
About Atrys Health
Atrys Health SA is a Spain based biomedical company which focuses on developing tools for the diagnosis and treatment of cancer and precancerous conditions. It offers diagnostic services in the fields of pathology, hematology, molecular pathology, and genetics. The company uses telemedicine to provide its services in the medical specialties of radiology, cardiology, ophthalmology, and dermatology.
Founded
2007
HQ
Employees
62
Website
Sectors
Financials (LTM)
EV
$557M
Atrys Health Financials
Atrys Health reported last 12-month revenue of $176M and EBITDA of $33M.
In the same LTM period, Atrys Health generated $90M in gross profit, $33M in EBITDA, and had net loss of ($5M).
Revenue (LTM)
Atrys Health P&L
In the most recent fiscal year, Atrys Health reported revenue of $166M and EBITDA of $30M.
Atrys Health expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $176M | XXX | $166M | XXX | XXX | XXX |
| Gross Profit | $90M | XXX | $72M | XXX | XXX | XXX |
| Gross Margin | 51% | XXX | 44% | XXX | XXX | XXX |
| EBITDA | $33M | XXX | $30M | XXX | XXX | XXX |
| EBITDA Margin | 19% | XXX | 18% | XXX | XXX | XXX |
| EBIT Margin | 3% | XXX | 2% | XXX | XXX | XXX |
| Net Profit | ($5M) | XXX | ($4M) | XXX | XXX | XXX |
| Net Margin | (3%) | XXX | (2%) | XXX | XXX | XXX |
| Net Debt | — | — | $258M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Atrys Health Stock Performance
Atrys Health has current market cap of $269M, and enterprise value of $557M.
Market Cap Evolution
Atrys Health's stock price is $3.55.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $557M | $269M | -1.2% | XXX | XXX | XXX | $-0.05 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialAtrys Health Valuation Multiples
Atrys Health trades at 3.2x EV/Revenue multiple, and 16.9x EV/EBITDA.
EV / Revenue (LTM)
Atrys Health Financial Valuation Multiples
As of April 18, 2026, Atrys Health has market cap of $269M and EV of $557M.
Equity research analysts estimate Atrys Health's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Atrys Health has a P/E ratio of (55.9x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $269M | XXX | $269M | XXX | XXX | XXX |
| EV (current) | $557M | XXX | $557M | XXX | XXX | XXX |
| EV/Revenue | 3.2x | XXX | 3.4x | XXX | XXX | XXX |
| EV/EBITDA | 16.9x | XXX | 18.4x | XXX | XXX | XXX |
| EV/EBIT | 95.0x | XXX | 141.3x | XXX | XXX | XXX |
| EV/Gross Profit | 6.2x | XXX | 7.7x | XXX | XXX | XXX |
| P/E | (55.9x) | XXX | (67.2x) | XXX | XXX | XXX |
| EV/FCF | 433.5x | XXX | (483.8x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Atrys Health Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Atrys Health Margins & Growth Rates
Atrys Health's revenue in the last 12 month grew by 21%.
Atrys Health's revenue per employee in the last FY averaged $2.7M, while opex per employee averaged $1.3M for the same period.
Atrys Health's rule of 40 is 44% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Atrys Health's rule of X is 83% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Atrys Health Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 21% | XXX | 26% | XXX | XXX | XXX |
| EBITDA Margin | 19% | XXX | 18% | XXX | XXX | XXX |
| EBITDA Growth | 23% | XXX | 30% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 44% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 83% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $2.7M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $1.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 0% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 3% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 48% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Atrys Health Public Comps
See public comps and valuation multiples for other Diagnostics & Genomics and Medical Imaging & Diagnostics comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Atrys Health | XXX | XXX | XXX | XXX | XXX | XXX |
| Healius | XXX | XXX | XXX | XXX | XXX | XXX |
| Australian Clinical Labs | XXX | XXX | XXX | XXX | XXX | XXX |
| Humana | XXX | XXX | XXX | XXX | XXX | XXX |
| Prenetics Global | XXX | XXX | XXX | XXX | XXX | XXX |
| OncoclÃnicas | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Atrys Health M&A Activity
Atrys Health acquired XXX companies to date.
Last acquisition by Atrys Health was on XXXXXXXX, XXXXX. Atrys Health acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Atrys Health
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialAtrys Health Investment Activity
Atrys Health invested in XXX companies to date.
Atrys Health made its latest investment on XXXXXXXX, XXXXX. Atrys Health invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Atrys Health
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Atrys Health
| When was Atrys Health founded? | Atrys Health was founded in 2007. |
| Where is Atrys Health headquartered? | Atrys Health is headquartered in Spain. |
| How many employees does Atrys Health have? | As of today, Atrys Health has over 62 employees. |
| Is Atrys Health publicly listed? | Yes, Atrys Health is a public company listed on Bolsa de Madrid. |
| What is the stock symbol of Atrys Health? | Atrys Health trades under ATRY ticker. |
| When did Atrys Health go public? | Atrys Health went public in 2016. |
| Who are competitors of Atrys Health? | Atrys Health main competitors are Healius, Australian Clinical Labs, Humana, Prenetics Global. |
| What is the current market cap of Atrys Health? | Atrys Health's current market cap is $269M. |
| What is the current revenue of Atrys Health? | Atrys Health's last 12 months revenue is $176M. |
| What is the current revenue growth of Atrys Health? | Atrys Health revenue growth (NTM/LTM) is 21%. |
| What is the current EV/Revenue multiple of Atrys Health? | Current revenue multiple of Atrys Health is 3.2x. |
| Is Atrys Health profitable? | Yes, Atrys Health is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Atrys Health? | Atrys Health's last 12 months EBITDA is $33M. |
| What is Atrys Health's EBITDA margin? | Atrys Health's last 12 months EBITDA margin is 19%. |
| What is the current EV/EBITDA multiple of Atrys Health? | Current EBITDA multiple of Atrys Health is 16.9x. |
| What is the current FCF of Atrys Health? | Atrys Health's last 12 months FCF is $1M. |
| What is Atrys Health's FCF margin? | Atrys Health's last 12 months FCF margin is 1%. |
| What is the current EV/FCF multiple of Atrys Health? | Current FCF multiple of Atrys Health is 433.5x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.